AU2002221096A1 - Medicinal compositions improved in solublity in water - Google Patents
Medicinal compositions improved in solublity in waterInfo
- Publication number
- AU2002221096A1 AU2002221096A1 AU2002221096A AU2109602A AU2002221096A1 AU 2002221096 A1 AU2002221096 A1 AU 2002221096A1 AU 2002221096 A AU2002221096 A AU 2002221096A AU 2109602 A AU2109602 A AU 2109602A AU 2002221096 A1 AU2002221096 A1 AU 2002221096A1
- Authority
- AU
- Australia
- Prior art keywords
- solublity
- water
- medicinal compositions
- compositions improved
- improved
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-375601 | 2000-12-11 | ||
JP2000375601 | 2000-12-11 | ||
PCT/JP2001/010768 WO2002048141A1 (en) | 2000-12-11 | 2001-12-10 | Medicinal compositions improved in solublity in water |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2002221096A1 true AU2002221096A1 (en) | 2002-06-24 |
Family
ID=18844590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2002221096A Abandoned AU2002221096A1 (en) | 2000-12-11 | 2001-12-10 | Medicinal compositions improved in solublity in water |
Country Status (10)
Country | Link |
---|---|
US (1) | US20040058956A1 (en) |
EP (1) | EP1350792A1 (en) |
KR (1) | KR20040025880A (en) |
CN (1) | CN1487935A (en) |
AU (1) | AU2002221096A1 (en) |
CA (1) | CA2431319A1 (en) |
HU (1) | HUP0401811A2 (en) |
NO (1) | NO20032613L (en) |
PL (1) | PL362979A1 (en) |
WO (1) | WO2002048141A1 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
WO2003031442A1 (en) * | 2001-10-05 | 2003-04-17 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof |
MXPA04002602A (en) | 2002-02-28 | 2004-08-11 | Japan Tobacco Inc | Ester compound and medicinal use thereof. |
WO2004096281A1 (en) * | 2003-04-29 | 2004-11-11 | Kowa Co., Ltd. | Composition containing medicine extremely slightly soluble in water being excellent in eluting property and method for preparation thereof |
MY147403A (en) * | 2003-04-29 | 2012-11-30 | Kowa Co | Composition containing medicine extremely slightly solube in water and method for preparation thereof |
US20060030623A1 (en) * | 2004-07-16 | 2006-02-09 | Noboru Furukawa | Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis |
MY191349A (en) | 2004-08-27 | 2022-06-17 | Bayer Pharmaceuticals Corp | New pharmaceutical compositions for the treatment of hyper-proliferative disorders |
US8101774B2 (en) | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
BRPI0516772A (en) * | 2004-10-25 | 2008-09-23 | Japan Tobacco Inc | solid formulation with improved solubility and stability and method for producing said formulation |
EP1814544A4 (en) * | 2004-11-05 | 2009-12-02 | Cephalon Inc | Cancer treatments |
US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
EP1767194A1 (en) * | 2005-06-09 | 2007-03-28 | Helm AG | Process for the preparation of adsorbates of drospirenone |
WO2006137595A1 (en) * | 2005-06-24 | 2006-12-28 | Takeda Pharmaceutical Company Limited | Prophylactic/therapeutic agent for her2-expressing cancer |
CA2622944A1 (en) * | 2005-09-30 | 2007-04-12 | F. Hoffmann-La Roche Ag | Diazine azole derivatives, their manufacture and use as pharmaceutical agents |
KR100767349B1 (en) * | 2006-08-01 | 2007-10-17 | 삼천당제약주식회사 | A pharmaceutical composition for oral comprising fenofibrate and preparation method thereof |
AR065720A1 (en) | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | RECONSTITUTION POWERS THAT INCLUDE RILPIVIRINE DISPERSED IN CERTAIN POLYMERS. USE. PROCESS. |
AR072777A1 (en) | 2008-03-26 | 2010-09-22 | Cephalon Inc | SOLID FORMS OF BENDAMUSTINE CHLORHYDRATE |
CA2735899A1 (en) | 2008-09-25 | 2010-04-01 | Cephalon, Inc. | Liquid formulations of bendamustine |
SG172810A1 (en) * | 2009-01-15 | 2011-08-29 | Cephalon Inc | Novel forms of bendamustine free base |
EP2581084A4 (en) * | 2010-05-31 | 2014-06-25 | Astellas Pharma Inc | Solid dispersion comprising triazole compound |
AU2011332031B2 (en) | 2010-11-24 | 2017-01-12 | Melinta Subsidiary Corp. | Pharmaceutical compositions |
PT2765990T (en) * | 2011-10-14 | 2017-11-14 | Array Biopharma Inc | Solid dispersion |
CN103070828B (en) * | 2011-10-26 | 2016-01-27 | 山东新时代药业有限公司 | A kind of solid dispersion, tablet and preparation method thereof containing Abiraterone acetate |
EP4101297A1 (en) * | 2013-03-15 | 2022-12-14 | Aerpio Pharmaceuticals, Inc. | Compositions, formulations and methods for treating ocular diseases |
CN106232144B (en) | 2014-03-18 | 2019-12-06 | 武田药品工业株式会社 | Solid dispersion |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5352617A (en) * | 1976-10-25 | 1978-05-13 | Shin Etsu Chem Co Ltd | Solid drug coating composition |
IT1183574B (en) * | 1985-05-08 | 1987-10-22 | Eurand Spa | METHOD FOR OBTAINING A HOMOGENEOUS ETHERPORARY SUSPENSION OF MICROCAPS |
WO1996019239A1 (en) * | 1994-12-21 | 1996-06-27 | Yamanouchi Pharmaceutical Co., Ltd. | Solid composition with improved solubility and absorbability |
EP2070920B8 (en) * | 1996-07-24 | 2011-04-27 | Celgene Corporation | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels |
EP0995435B1 (en) * | 1997-05-14 | 2007-04-25 | Senju Pharmaceutical Co., Ltd. | Aqueous suspension preparations with excellent redispersibility |
-
2001
- 2001-12-10 PL PL01362979A patent/PL362979A1/en not_active Application Discontinuation
- 2001-12-10 CA CA002431319A patent/CA2431319A1/en not_active Abandoned
- 2001-12-10 KR KR10-2003-7007740A patent/KR20040025880A/en not_active Application Discontinuation
- 2001-12-10 US US10/433,507 patent/US20040058956A1/en not_active Abandoned
- 2001-12-10 CN CNA018224024A patent/CN1487935A/en active Pending
- 2001-12-10 AU AU2002221096A patent/AU2002221096A1/en not_active Abandoned
- 2001-12-10 WO PCT/JP2001/010768 patent/WO2002048141A1/en not_active Application Discontinuation
- 2001-12-10 EP EP01270217A patent/EP1350792A1/en not_active Withdrawn
- 2001-12-10 HU HU0401811A patent/HUP0401811A2/en unknown
-
2003
- 2003-06-10 NO NO20032613A patent/NO20032613L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
PL362979A1 (en) | 2004-11-02 |
US20040058956A1 (en) | 2004-03-25 |
CN1487935A (en) | 2004-04-07 |
NO20032613D0 (en) | 2003-06-10 |
WO2002048141A1 (en) | 2002-06-20 |
KR20040025880A (en) | 2004-03-26 |
NO20032613L (en) | 2003-08-05 |
HUP0401811A2 (en) | 2004-12-28 |
EP1350792A1 (en) | 2003-10-08 |
CA2431319A1 (en) | 2002-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002221096A1 (en) | Medicinal compositions improved in solublity in water | |
GB2358582B (en) | Pharmaceutical compositions | |
AU6219601A (en) | Pharmaceutical compositions | |
HK1064601A1 (en) | Pharmaceutical compositions comprising amlodipene maleate | |
GB0009584D0 (en) | Pharmaceutical compositions | |
AU8576801A (en) | Pharmaceutical compositions | |
AU2002214324A1 (en) | Medicinal compositions | |
HK1057474A1 (en) | Medicinal composition | |
AU1390002A (en) | Pharmaceutical compositions | |
GB0008485D0 (en) | Pharmaceutical compositions | |
GB0009613D0 (en) | Pharmaceutical compositions | |
AU8254101A (en) | Medicinal compositions | |
GB2363073B (en) | Oral rehydration formulation | |
AU2001282541A1 (en) | Medicinal compositions | |
GB0015361D0 (en) | Improvements in pharmaceutical compositions | |
AU2002248155A1 (en) | Cleansing composition | |
GB0023054D0 (en) | Improvements in aqueous compositions | |
GB0006380D0 (en) | Polymer preparation | |
AUPQ523300A0 (en) | Improvements in water treatment compositions | |
GB0015360D0 (en) | Improvements in pharmaceutical compositions | |
AUPQ991200A0 (en) | Improvements in or relating to dispensers | |
AUPQ432199A0 (en) | Improvements in water treatment compositions | |
AUPQ271499A0 (en) | Improvements in water treatment compositions | |
AUPQ999300A0 (en) | Improvements in water treatment | |
AUPQ821200A0 (en) | Improvements in water treatment |